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Cell therapyParkinson's disease (PD) involves the loss of dopamine (DA) neurons, making it the most expected
neurodegenerative disease to be treated by cell replacement therapy. Stem cells are a promising source for
cell replacement therapy due to their ability to self-renew and their pluripotency/multipotency that allows
them to generate various types of cells. However, it is challenging to derive midbrain DA neurons from stem
cells. Thus, in this review, I will discuss the molecular factors that are known to play critical roles in the
generation and survival of DA neurons. The developmental process of DA neurons and functions of extrinsic
soluble factors and homeodomain proteins, forkhead box proteins, proneural genes, Nurr1 and genes
involved in epigenetic control are discussed. In addition, different types of stem cells that have potential for
future cell replacement therapy are reviewed.l rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Stem cells are an attractive source of cells for use in regenerative
medicine, although further characterization and a more reﬁned
differentiation protocol are needed before they can be widely used.
Stem cells have unlimited proliferative properties and possess
pluripotent/multipotent differentiation abilities. Embryonic stem
(ES) cells are derived from the inner cell mass of an embryo and
can be induced to produce all of the types of cells in the human body,
including dopamine (DA) neurons or motor neurons [1]. Neural stem
cells (NSC) also have the ability to generate central nervous system
(CNS) cell types such as neurons and glia, with limited proliferation
potential [2]. Recently, induced pluripotent stem (IPS) cells were
developed as a promising cell source to generate disease-speciﬁc and
personally tailored cells [3–6].
Parkinson's disease (PD) is characterized by the progressive loss of
DA neurons in the substantia nigra (SNc) and results in symptoms like
tremor, bradykinesia and muscle rigidity. Due to the loss of DA
neurons located in a speciﬁc region of the brain, PD has been
considered a major target disease model that may be suitable for cell
therapy. Indeed, several clinical trials using cells derived from fetal
midbrain have demonstrated cell therapy potential [7–12]. To
overcome limited supply of fetal tissues, the derivation of DA neurons
from stem cells has been intensely studied. In addition, in order to be
used in clinical setting, stem cells must be efﬁciently differentiated
into right typemidbrain DA (midDA) neurons, and potential problemsrelated to the possible generation of teratomas or transplantation
rejection have to be resolved. Thus, in this review, I will focus on
recent advances in stem cell biology and on molecular factors
involved in the generation of DA neurons.
2. PD and cell therapy
PD is a major neurodegenerative disease that affects almost 2% of
the population above the age of 65. midDA neurons in the SNc project
to the dorsolateral striatum, caudate and putamen forming the
nigrostriatal pathway and release DA, an important neurotransmitter
that controls body movement [13]. In PD, degeneration midDA
neurons in the SNc with reduced DA levels in the striatum results in
deﬁcits of motor control [13,14]. Currently, available therapies for the
treatment of PD address symptoms but are not cures. Pharmacological
treatments such as L-dihydroxyphenyalanine (L-DOPA) or DA recep-
tor agonists reduce symptoms only in early stages of the disease,
while chronic use of L-DOPA aggravates the condition [15]. This is
referred to as “L-DOPA paradox.”
Brain stimulation treatments in the subthalamic nucleus or globus
pallidus are also effective for relieving symptoms of PD [16]. Direct
infusion of glial cell line-derived neurotrophic factor (GDNF) was also
shown to be effective in clinical trials [17]. However, while these
methods may protect neurons from dying, they do not regenerate
impaired midDA neurons and may also affect other target tissues or
cells, resulting in unwanted effects.
A potential treatment for PD is to transplant developing fetal
midbrain tissues to the striatum, and so far, the results appear
promising [7–12]. However, the survival of transplanted cells in
patients' brains is typically very low and the results are variable. Some
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period, whereas others do not [9–11,18]. In a double-blind trial,
patients transplanted with fetal tissues did not improve signiﬁcantly
although they showed better overall treatment effects than thosewith
placebo [19]. In another double-blind trial, fetal DA neuron trans-
plants survived in patients with severe PD and showed clinical
beneﬁts in younger patients but not in older patients [9]. These
inconsistent results may be due to variation in the transplanted fetal
cells, since the conditions of the cells and collection or preparation
protocols vary among clinical trials [9–11,18]. Thus, the quality of
transplantable cells should also be standardized. However, with the
limited supply of fetal midbrain-derived cells, this is an unrealistic
goal. Theoretically, stem cells can be propagated indeﬁnitely and be
manipulated towards a certain cell fate.
Therefore, generating midDA neurons and identifying molecules
that are essential for midDA neurogenesis from stem cells remains an
intense research area. Several factors, such as orthodenticle homeo-
box 2 (OTX2), Lim1a, Lim1b, orphan nuclear receptor-related factor1
(Nurr1), tyrosine hydroxylase (TH), paired-like homeodomain 3
(Pitx3), ﬁbroblast growth factor 8 (FGF8), sonic hedge hog (SHH),
Engrailed genes (En1, En2), Wingless (Wnt), Forkhead box protein
(Fox) A2 and neurogenin (Ngn) 2 have been implicated as important
factors in DA neuron development, although the mechanisms
underlying the development of DA neurons are not yet fully
understood.
3. Factors involved in DA neurogenesis
3.1. Expression sequence of factors involved in DA neurogenesis
In this section, I will discuss the expression sequence of extrinsic
and intrinsic factors that contribute to DA neurogenesis in order to
explain the interplay among molecules that confer the ventral
midbrain phenotype, DA phenotype and neurogenesis (Fig. 1). The
detailed roles of each factor in the generation of DA neurons are
addressed in the following sections.
In the developingmouse, FGF8 is expressed between E8.0 and E8.5,
in the region between the prospective midbrain and hindbrain [20].
From E9.0 to E12.5, FGF8 is observed in the isthmus (hindbrain and
midbrain border) and from E8.5, SHH signaling from the ﬂoor plate
inﬂuences the progenitor domain and provides molecular signals to
specify DA neurons [20–25]. FoxA2 is proposed to regulate SHH and
its expression precedes that of SHH in the ventral CNS [25]. Wnt1 is
also reported to be expressed in the open neural plate around E8.0 andE7.0 E8.0 E9.0 E10.0
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Fig. 1. Molecular factors that play essential roles in the development of DA neurons. The seq
factors, FGF8 from the isthmus and SHH from the ﬂoor plate, provide anterior-posterior and
Lmx1b expression is maintained by FGF8 and affects the expression andmaintenance ofWnt1
to be necessary and sufﬁcient for antagonizing SHH. Lmx1a is induced by SHH and maintain
which plays an important role in neurogenesis. Lmx1a is reported to regulate Nurr1 and Pitx
Pitx3 expression. Ectopic expression of FoxA2 induces expression of Nurr1, Pitx3, TH, AADC
induces expression of TH, a critical enzyme required for the synthesis of DA. Nurr1 is also invo
may regulate TH expression. Pitx3 increases the expression of ADH2 in the midbrain DA neis known to be expressed in the vicinity of the isthmus in an area
immediately rostral to FGF8 at E9.5 [20,26]. The Wnt-1 expression at
E12.5, if any, seems to be punctuated in several small regions in the
midbrain [26,27]. En1 and En2 are ﬁrst expressed in the presumptive
midbrain at about the same time as Wnt1 (at E8.0); however, by
12 days of embryonic development, the expression patterns of these
three genes diversify and the overlapping regions are restricted [27].
The expression of homeodomain (HD) protein Lmx1a is observed
around E9.0 and is maintained in postmitotic DA neurons [28,29]. The
HD transcription factor Msx1 expression is ﬁrst observed from E9.5
when Nkx6.1, an HD protein that is expressed in ventral progenitor
cells, starts to be downregulated [29]. Unlike Lmx1a, Msx1 expression
is restricted to dividing progenitor cells in the ventral midbrain [29].
Another LIM HD transcription factor, Lmx1b, is reported to be
expressed in the CNS from E7.5 and regulates the midDA neuron-
speciﬁc HD gene Pitx3 [30]. There are discrepancies regarding the
reported expression timing of Lmx1b, in that Smidt and colleagues
reported that Lmx1b expression is maintained throughout life in the
ventral midbrain, whereas other groups have shown that it is
terminated around E11.5 [29–31]. The expression of Pitx3, a bicoid-
related homeobox gene, starts at E11.5 and is correlated with the
appearance of midDA neurons [32]. Ngn2 begins to be expressed at
around E10.75 and its expression is maintained in mitotic progenitor
cells in the ventral midbrain, even after TH-positive neurons are born
[29,33]. Nurr1 is a member of the thyroid hormone/RA nuclear
receptor superfamily and is important in the induction of TH
expression. Nurr1 is found in the ventral midbrain from E10.5, 1 day
before the appearance of TH [34–38].
3.2. Extrinsic factors affecting development of DA neurons
Cell fate determination is affected during development by both
extrinsic and intrinsic factors of progenitor cells. Extrinsic soluble
factors are secreted by developing tissues or cells and provide speciﬁc
local cues to impose positional addresses. For example, SHH is a
morphogenic factor released from the ﬂoor plate that induces a
general ventral cell fate and also plays a critical role in the
development of the ventral midbrain, where DA neurons are found
[22,39]. In addition, SHH facilitates proliferation of precursors of DA
neurons [31], although high expression levels of SHH correlate with
inhibitory effects on progenitor cell proliferation and DA neuron
production [40]. Intersecting with SHH expression, FGF8, produced by
the isthmus organizer is also involved in the speciﬁcation of DA
neurons [21]. The dorso-ventral information provided by SHH andE11.0 E12.0
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uence of appearance and effects of each molecule on others are shown. Two diffusible
dorso-ventral cues for the generation of DA neurons. In early midbrain development,
. Wnt1 regulates En1 and En2 expression. In addition,Wnt signaling was recently found
ed by FoxA1/2. Msx1 functions as a downstream molecule of Lmx1a and induces Ngn2,
3. Another HD protein, Lmx1b, is maintained by FGF8 and known to regulate Nurr1 and
, VMAT and DAT, and this may occur indirectly via Lmx1a and/or Lmx1b. Nurr1 directly
lved in regulation of c-Ret, VMAT, DAT and AADC. Pitx3, while not involved in induction,
urons.
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cursors and further promote DA neurogenesis.
Members of the Wnt family are additional factors expressed and
secreted in the midbrain and are involved in cellular events such as
precursor cell proliferation, neuronal differentiation and cell fate
determination [41]. Among Wnt family members, Wnt1, 3a and 5a
have been reported to play critical roles in DA neuron development
[42,43]. DA precursor cells express beta-catenin and are affected by
Wnt signaling [43]. A recent study suggested that Wnt/beta-catenin
signaling is necessary and sufﬁcient for antagonizing SHH, and
reduced levels of SHH in the midline of the midbrain induce
proliferation of precursor cells and DA neuron production [40]. In
vivo experiments using Wnt1 mutant mice showed a loss of most
of the midbrain and DA neurons, and ectopic expression of Wnt1
and Wnt5a increased the numbers of DA neurons in NSC cultures
[43–45]. When overexpressed in NSC, Wnt1 increased proliferation
of Nurr1+ precursors, and upregulated cyclin D1 and D3, whereas
Wnt5a enhanced proliferation of DA precursors to a lesser extent
and induced transcription of Pitx3 and c-ret [43]. Wnt3a promoted
Nurr1-expressing precursor cells without increasing the number of
TH-positive neurons [43]. Wnt signaling is also important in
maintaining the expression of En genes, which are crucial for DA
neurogenesis [45,46]. The Wnt signaling targets the En2 promoter
and initiates and maintains En2 expression [45,47]. In Wnt1
mutant mice, En1 was sufﬁcient to rescue early midbrain and
hindbrain developmental defects [45]. In double En1 and En2
mutant mice, DA neurons were generated but were lost soon after
differentiation, suggesting that En genes are involved in survival
rather than speciﬁcation of DA neurons [48].
3.3. Intrinsic factors involved in the generation of DA neurons
3.3.1. Homeodomain proteins
Several HD factors, including Otx2, Lmx1a, Msx1, Lmx1b and Pitx3,
are known to be involved in DA neuron development and are affected
by extrinsic factors. Otx2 is induced byWnt1, and conditional deletion
of Otx2 results in reduced levels of DA neurons [49–51]. This
phenotype was rescued by deletion of Nkx2.2, suggesting that Otx2
is a factor that represses Nkx2.2 [50].
“Mother nature” appears to have a common way, if not too much
over-simpliﬁed, to diversify the types of neurons. As shown by Jessell
and colleagues, extrinsic factors such as SHH, FGF and retinoic acid
induce distinct transcription factors in motor neuron progenitor cells
in the spinal cord [52,53]. For the generation of diverse types of motor
neurons, distinct Fox proteins and LIM HD proteins are induced to
control positional properties and subtype identities [52,53]. Similar to
spinal cord development, during midbrain formation, FoxA1 and
FoxA2 are speciﬁcally expressed and Lmx1a, an LIM HD protein, is
induced by SHH and plays a pivotal role in the DA neuron speciﬁcation
[29]. As clearly shown in experiments using chick embryos, over-
expression of Lmx1a results in ectopic production of DA neurons
whereas knocking down Lmx1a reduced DA neurogenesis [29]. In
addition, Lmx1a induced DA-speciﬁc properties and its downstream
molecule Msx1 that functions as Groucho/TLE-dependent repressor of
Nkx6.1 [29]. By repressing Nkx6.1, an essential molecule that is
required for the generation of motor neurons, Msx1 appears to
provide an environment that favors DA neurogenesis [29,54]. Msx1
regulates neurogenesis by induction of proneural gene, Ngn2, and
therefore controls the timing of DA neurogenesis [29].
Lmx1b is another HD protein that is implicated in midbrain-
speciﬁc DA neurogenesis and its loss results in expression of Pitx3
[30]. However, Nurr1 and TH were expressed normally in the Lmx1b
null mice [30]. In early midbrain development, it has been reported
that Lmx1b functions as an effector of FGF8 in the regulation of Wnt1
[55]. FoxA1 and FoxA2 proteins are shown to positively regulate
Lmx1a and Lmx1b expression and function cooperatively with theseHDs to induce differentiation of DA neurons [56]. Detailed roles of Fox
proteins in DA neurogenesis and PD are addressed in section 3.3.4. It is
intriguing that genes such as Lmx1a, Msx1 and Lmx1b, which are
known to play critical roles in speciﬁcation of dorsal cell fates and
roof-plate cells, are essential for the development of the ventral
midbrain DA neurons.
Pitx3, which is regulated by Lmx1b, is expressed in the eye, muscle
and midbrain. Mutation in Pitx3 affects eye development and is
known to cause cataracts [57]. Although the levels of overlapping
expression of Pitx3 and TH are somewhat differently reported, Pitx3
has been shown to be expressed in TH-positive neurons in the
midbrain [32,58,59]. Observations from aphakia mice, which have
deletions in the enhancer region, promoter region and exon 1 of Pitx3
gene, indicated that Pitx3 does not affect initial development but
terminal differentiation, maintenance, survival and migration of the
midbrain TH-positive DA neurons [60]. In aphakia mice, although the
expression of TH was not altered in early development of DA neurons
at E11.5, it has been reported that Pitx3 may regulate TH transcription
[61–63]. Pitx3 speciﬁcally increases the expression of aldehyde
dehydrogenase (ADH) 2 which is expressed in midDA neurons [62].
3.3.2. Proneural genes
Proneural genes such as genes encoding basic helix–loop–helix
(bHLH) proteins are required for neurogenesis. The proneural bHLH
proteins act as transcriptional activators by binding to sequences
known as E boxes through the basic regions of the proteins. The HLH
part is involved in protein contact, and these proteins function as
homo- or heterodimers. Among bHLH proteins, murine achaete
schute homologue 1 (Mash1) and Ngn2 are speciﬁcally expressed in
the progenitor domain of the developing midbrain [29,33,64].
Although the expressions of Mash1 and Ngn2 are regionally distinct
in the neural system, it is noted that they are co-expressed in the
progenitor domain of the midbrain [33]. However, the interplay of
Ngn2 and Mash1 in DA neurogenesis is largely unknown.
Ngn2 is regulated by Lmx1a and its downstream target, Msx1, and
in the absence of Ngn2, development of DA neurons is compromised
[29]. However, when ectopically expressed, bHLH proteins only
induce neurogenesis, and DA cell-speciﬁc properties were not
modulated by these factors [33].
3.3.3. Orphan receptor Nurr1
DA is a neurotransmitter that controls motor function and is
synthesized from tyrosine. DA neurons should possess adequate
machinery to convert tyrosine to DA. The ﬁrst and rate limiting step to
produce DA is the production of DOPA. TH is the critical enzyme for
this step and is used as a DA neuronal marker. Thus, molecules
essential for TH expression are being intensely studied. The
dopaminergic system is not only involved in motor control, but also
in controlling rewardmechanisms, emotion and perception. There are
three important DA pathways that are found in the CNS, nigrostriatal
pathway, in which DA neurons originate in the SNc and innervate the
striatum, mesolimbic pathway, where DA neurons in the ventral
tegmental area (VTA) connect the amygdale, septal nuclei and
cingulated gyrus, and mesocortical pathway, in which DA neurons
generated in the VTA make connection to the cortex. The nigrostriatal
pathway is important in motor control, whereas abnormal control of
mesolimbic system is known to be related in schizophrenia.
Nurr1 is pivotal for successful TH expression [35–38] and its
mutations are associated with PD and schizophrenia [65–67]. Nurr1
activates TH expression by directly binding to the promoter [68].
Nurr1 can bind to a speciﬁc DNA sequence known as the NGFI-B
response element (NRBE:AAAGGTA) and its binding to NRBE on the
promoter of TH leads to induction of TH transcription [68,69]. Nurr1 is
also known to induce dopamine transporter (DAT) transcription via
an NBRE-independent mechanism [70]. DA phenotype-related genes
including L-amino acid decarboxylase (AADC) and vesicular
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lated by Nurr1 [71]. A recent genome-wide analysis identiﬁed new
targets genes of Nurr1 including Dlk1, Ptpru and Klhl1. Pitx3 regulated
expression of target genes cooperatively with Nurr1 [72]. Pitx3 is
suggested to potentiate transcriptional effects of Nurr1 by inducing
the release of transcriptional repressor SMRT [72,73]. Nurr1 can
activate transcription as a monomer or by heterodimerization with
retinoic X receptor (RXR) [74]. The ligands of Nurr1 have not been
identiﬁed, and thus it is referred to as an “orphan receptor.” However,
the X-ray crystallography structure of Nurr1 mimics a transcription-
ally active, ligand-bound protein fold, suggesting that it may function
in a ligand-independent manner [75].
Nurr1 can be regulated by the cAMP/PKA pathway via its promoter,
which contains a cAMP response element [76]. Nurr1 can be induced by
corticotrophin releasing factor and parathyroid hormone in a pituitary
cell line and bone cells, respectively [77,78]. Treatment with PKA
activator, forskolin, induces Nurr1 and inhibition of PKA signiﬁcantly
reducesNurr1 activation in these systems, suggesting that the activation
of Nurr1 is mediated by the PKA pathway [77,78]. Recently, FoxA1 and
FoxA2 were reported to be required for the expression of Nurr1 in a
dosage-dependentmanner [79]. In FoxA1/2 doublemutant mice, Nurr1
expression was dramatically reduced. In addition, direct evidence for
FoxA2-mediatedNurr1expressionhas been shown inagain-of-function
study [80]. In the absence of FoxA1 or FoxA2, the numbers of immature
Nurr1-expressing cells without TH expression increased, suggesting
that FoxA1/2 protein may contribute to facilitating the ﬁnal differen-
tiation of DA neurons in response to Nurr1 [79]. However, in the ventral
midbrain, howNurr1 expression is activated and regulated is still largely
unknown.
Nurr1 affects TH expression/DA neuron development and survival
of DA neuron [37,38]. Nurr1 mutant mice fail to generate DA neurons
and die soon after birth, conﬁrming an essential role of Nurr1 in DA
neurogenesis [37,38,81]. Mice lacking Nurr1 lose DA neurons in the
SNc and VTA, and the expression of TH and AADC and c-ret is
abolished [37,38]. Interestingly, Nurr1 heterozygote mice are healthy
but show signiﬁcantly reduced DA levels in the striatum and ventral
midbrain [38]. Similar to this ﬁnding, ectopic expression of Nurr1 in
NSC induce TH in a concentration dependent manner [33]. These data
suggest that high levels of Nurr1 may be needed to induce TH or DA
neuronal phenotypes. Nurr1 expression lasts a lifetime in DA neurons,
suggesting that it plays a role in other processes, in addition to
development of DA neurons, such as cell survival and maintenance
[82,83]. When Nurr1 was conditionally ablated at late stage of midDA
neuron development or in the adult brain, loss of striatal DA, loss of
midbrain markers and neurodegeneration was observed, suggesting
its essential role in the maturation and maintenance of DA neurons
[84]. Interestingly, DA neurons in SNc were more vulnerable than
those in VTA [84]. Recently, Nurr1 has been reported to trans-repress
inﬂammatory genes in both microglia and astrocytes [85]. Upon
inﬂammatory stimuli, Nurr1 is post-transcriptionally modiﬁed
(sumoylated) and recruits CoREST, HDAC1 and LSD1 corepressor
complex and clears the p65 NF-κB [85]. Thus, Nurr1 has roles beyond
that of a transcriptional activator by limiting the production of
neurotoxicity against inﬂammation by microglia and astrocytes and
protecting DA neurons.
3.3.4. Fox proteins
Fox protein family members are transcriptional regulators that can
be divided into 19 classes, referred to as FoxA to FoxS, and they play
important roles in differentiation, organ development and cancer [86].
All Fox proteins have an ~100-bp forkhead DNA binding domain and
its structure resembles that of the linker histone H1 and is known to
open condensed chromatin [87,88]. In the case of FoxA1 in estrogen
receptor- and androgen receptor-mediated transcription, it is differ-
entially recruited to the chromatin and collaborates with the nuclear
receptors at the lineage-speciﬁc enhancers [89–91]. In addition, thedistribution of histone H3 lysine 4 demethylation deﬁnes the
recruitment of FoxA1 [92]. Thus, Fox proteins may function as pioneer
proteins that translate speciﬁc epigenetic codes to establish lineage-
speciﬁc transcription.
Among those Fox protein families, FoxA1 and FoxA2 are known to
be expressed in an overlapping and distinct pattern in the midbrain
progenitor domain and in differentiated DA neurons during develop-
ment [31,33,56,80,93]. These Fox proteins have been reported to play
a critical role in DA neurogenesis [31,33,56,80,93]. FoxA2mutantmice
showed a defect in notochord formation, ﬂoor plate development and
dorsal-ventral pattering and died at E9.5 [94,95]. FoxA1 null mice
showed a defect in glucose homeostasis [96]. By using FoxA1 and
FoxA2 single and double mutants, the roles of these proteins during
speciﬁcation and differentiation of DA neurons have been explored
[56,79]. FoxA1 and FoxA2 regulated expression of Ngn2 and were
required for En1 and Nurr1 expression in immature DA neurons [79].
In mature DA neurons, the expression of TH and AADC was regulated
by FoxA1 and FoxA2 [79]. Interestingly, in each stage, a different
dosage of FoxA1/2 proteins was needed [79]. FoxA1 and FoxA2
maintained Lmx1a and Lmx1b expression and repressed Nkx2.2 and
the Helt gene, thus inhibiting GABAergic neurogenesis [56].
When ectopically introduced into NSC/or ES cells, FoxA2 induced
DA neurogenesis by inducing expression of TH, DA transporter,
VMAT 2, Nurr1, Wnt3a, Lmx1b, Corin, ADH2, Pitx3 and G-protein-
coupled inward rectiﬁer potassium [31,80], conﬁrming the essential
role of FoxA2 in DA neuron generation (Fig. 2A). It has also been
reported that Nurr1 synergistically cooperates with FoxAs to induce
DA phenotype acquisition, midbrain-speciﬁc gene expression and
neuronal maturation [80]. However, the mechanisms by which
FoxA1/2 proteins are able to induce such different molecules at
different stages are not known yet. In addition, it would be
interesting to explore how FoxA1 and FoxA2 induce genes involved
in DA neurogenesis while repressing other fate-related transcrip-
tion. As mentioned above, FoxA1/2 proteins may act as pioneer
factors and facilitate recruitment of transcription activation ma-
chinery to induce a variety of target genes (Fig. 2A). The diverse
function of FoxA protein at different stages may be due to changes
in binding partners during development of DA neurons. It is also
possible that changes in epigenetic status may affect the afﬁnity of
FoxA1/2 protein binding onto target promoter sites.
FoxA2, previously known as hepatocyte nuclear factor 3 (Hnf3), has
been proposed to activate SHH and is expressed prior to SHH [25,97].
However, the consensusbinding sites for FoxA2were identiﬁed in only a
subset of enhancer sites of SHH, suggesting that FoxA2-dependent
and -independent mechanisms exist to activate SHH gene expres-
sion [98]. A recent study reported that FoxA2 is a direct downstream
target of SHH [99]. FoxA2 has been reported to cooperate with Lmx1a
and Lmx1b to specify DA neurons by suppressing the Sim-Lhx1 and
Ngn1 pathways that inhibit DA neurogenesis [100].
Interestingly, FoxA1/2 proteins are also found in adult midDA
neurons, suggesting that they may also function as something other
than developmental factors. In aged mice, FoxA2 appears to be
involved in the survival of midDA neurons because heterozygote
mice missing a single FoxA2 allele developed parkinsonian-like
symptoms and pathologies [31]. In Caenorhabditis elegans, the FoxA
homolog is reported to induce antioxidant enzymes and is reported
to increase life span in response to diet restriction [101]. Somewhat
similar to the intensely studied FoxO protein [102], FoxA 1/2 may
also be involved in protecting against oxidative stress (Fig. 2B). The
differential developmental and maintenance roles of FoxA2 may
depend on the cellular context, although the exact mechanisms have
not been identiﬁed.
3.3.5. Genes involved in epigenetic control
Recent research indicates that epigenetic signatures contribute to
lineage-speciﬁc transcription [103,104]. Epigenetic control, or control
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Fig. 2. Possible mechanisms of FoxA1/2 in DA neurogenesis and survival. (A) FoxA proteins have a forkhead DNA binding domain with a structure that is similar to that of
linker histone. Thus, during development of DA neurons, FoxA proteins may function as pioneer proteins that replace linker histones and may provide space/structures that
favor transcriptional activators to access to the promoters of genes that are critical for DA neurogenesis. Many genes, including Ngn2, En1, Nurr1, TH, AADC, DAT, VMAT,
Wnt3a, Lmx1b, Corin, ADH2 and Pitx3, are known to be upregulated when FoxA2 is ectopically introduced to NSC or ES cells. (B) Although not much is known about how
FoxA2 heterozygotes are prone to PD, it is possible that, similar to FoxO proteins, FoxA proteins may play critical roles in protecting oxidative stresses by inducing
antioxidant enzymes such as superoxide dismutase.
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modiﬁcation and modiﬁcation by small non-coding RNAs, has been
known to play a critical role in determining the effects of transcription
factors and the cellular phenotype [105–107]. Especially, histone
modiﬁcation appears to contain “codes” for gene activation or
repression. Histone acetylation on lysine residues neutralizes the
interaction between the positively charged histone tail and negatively
charged DNA. As a consequence, it enables transcriptional factors to
access to the promoter or enhancer sites and results in transcriptional
activation. Thus, histone acetyl transferases (HATs) such as p300,
CREB binding protein (CBP), p300/CBP-associated factor (PCAF) and
general control of amino acid synthesis protein 5 (GCN5) are thought
to be important in gene transcription [108]. Since the amount of p300/
CBP is limited, transcription factors are competing to recruit these
proteins. During neurogenesis, Ngn1 shows predominant binding to
p300/CBP and by sequestrating HATs, it concurrently prevents
gliogenesis [109]. The histone deacetylase inhibitor, valproic acid,
induces neuronal differentiation and suppresses glial differentiation
in adult NSC, possibly by derepressing RE1 silencing transcription
factor (REST or NRSF) target genes [110]. REST is known to interact
with CoREST, NCoR and mSin3A to recruit a repressive HDAC-
containing epigenetic complex to neuron-speciﬁc genes [111–113].
Histones can also be methylated on speciﬁc lysines or arginines
and the methylated residues affect the status of transcription.
Methylation of histone 3 on lysine 4 (H3K4) is observed on
transcriptionally active promoters, whereas methylation on H3K9
and H3K27 is found on transcriptionally inactive regions [114,115].
Indeed, a histone H3 trimethyl K27 demethylase, JMJD3, was capable
of activating speciﬁc components of the neurogenic program [116],
suggesting a critical role in epigenetic control during neurogenesis.
Distinct dynamics and distribution of methyl H3K9 and H4K20 have
been reported in the development of the nervous system [117]. H3
trimethyl K9 and H4 monomethyl K20 were elevated in proliferating
cells of the neural tube, whereas the H4 trimethyl K20was enriched in
differentiating neurons [117]. Interestingly, undifferentiated stem
cells contain a distinct histone modiﬁcation pattern that is described
as “poised for later activation” [111]. The promoters of genes
expressed in later development were marked with both H3K27
methylation and H3K4 methylation [111].
It would be of great interest to explore histone modiﬁcation
patterns of genes with critical roles in midDA neurogenesis and todetermine the mechanisms by which lineage-speciﬁc histone modi-
ﬁcation occurs.
4. Potential stem cells for neuro-regeneration in PD therapy.
4.1. Neural stem cells (NSC)
NSC can be found in developing embryos or in the adult nervous
system [2]. Due to the diverse structures, various cell types and
complicated functions of the nervous system, it is difﬁcult to identify
and study NSC in vivo. Such cells can be found in the subventricular
zone and the hippocampus in the adult or in various regions of the
nervous system in developing embryos [2]. They divide symmetrically
to increase or maintain their numbers and asymmetrically to give rise
to differentiated progenies. NSCs are dissected and cultured in the
presence of mitogens, such as FGF2 or epidermal growth factor (EGF)
[33,118–120].
Although NSC have been studied intensively in the last few
decades, not much is known about how their self-renewal properties
aremaintained or how cell fate is determined [120]. TheWnt/-catenin
pathway, Notch signaling, SHH and transforming growth factor are
known to play important roles in the self-renewal of NSC [121]. NSC
can be induced to generate neurons, astrocytes or oligodendrocytes by
withdrawing mitogens or by adding factors such as PDGF, CNTF or
SHH and so on [2]. To induce NSC to a certain fate, soluble extrinsic
factors are added to the culture media or essential intrinsic factors
such as transcription factors are ectopically introduced to NSC. It has
been shown that TH-positive neurons were generated from FGF2-
expended NSCs, but only in early passages suggesting that primary
TH-positive neurons may be carried over at the time of dissection or
the cells expended may not be NSC but constantly differentiating
progenitor cells [122]. It is also possible that the culture conditions
need further optimization for NSC to generate DA neurons.
For the generation of DA neurons, transcription factors including
Nurr1, Ngn2, FoxA2 and other factors such as Bcl-XL were transduced/
transfected to the NSC [33,68,80,123]. After genetic engineering, NSC
are reported to acquire DA neuron-like phenotypes [124]. In some
cases, NSC without differentiation are transplanted into PD model
mice, resulting in behavior improvements by reducing apomorphine-
induced circling [125]. Although long-term cultured NSC were not
able to differentiate into DA neurons without genetic modiﬁcation,
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that they can only be differentiated into the cells that make up the
nervous system. With current technology, the differentiation protocol
is not fully established and ES cells can also produce cells other than
nervous cells and may form teratomas.4.2. Embryonic stem (ES) cells
The ﬁrst successful culturing of mouse ES cells using feeder cell
layers was reported in 1981 [126,127]. Seventeen years later, the
isolation of embryonic stem cells from the inner cell mass of human
blastocysts and the propagation in vitrowas reported by Thomson and
colleagues [128]. The advantage of using human ES cells is that early
human development can be explored and the potential for successful
cell therapy is high if speciﬁc types of cells that are degenerated under
pathological conditions can be induced. Even after prolonged passage,
human ES cells maintained their undifferentiated status and the
potential to differentiate into all three germ layers [128].
The culture conditions of human ES cells were different from those
of rodents in that mouse ES cell proliferation was induced by LIF and/
or BMP4, whereas human ES cell proliferation was mediated by FGF
and Activin/Nodal signaling [129,130]. To generate neural progenitors
from ES cells, generally, factors that promote self-renewal are
removed from the culture condition, and morphogens/extrinsic
factors are added [131]. Aggregation of ES cells provides signals that
mimic developmental events in vivo, in that the location/position of
cells and interactions with other cells also can promote differentiation
of ES cells. However, it is still a challenge to generate the right types of
neurons from human ES cells to be used in clinical settings, although
signiﬁcant progress has been made since the discovery of how to
maintain human ES cells. To induce the right types of cells, it is
important to understand the molecular mechanisms involved in the
generation of midDA neurons and to induce region-speciﬁc progeni-
tors and then region-speciﬁc neurons.
To generate midDA neurons, it has been suggested that early or
primitive neuroepithelial cells are advantageous since TH-positive
neurons generated using those cells co-express the midbrain
transcription factor En1, whereas late or deﬁnitive neuroepithelial
cell-derived TH neurons express forebrain transcription factor and
neurotransmitter [132]. In addition, human ES cells can be differen-
tiated into DA neurons in deﬁned serum-free media [133–135].
However, the efﬁciency of the resulting midDA neurons is low and
may require other extrinsic or intrinsic factors. Wnts and FGF8a may
play critical roles in the speciﬁcation of midbrain phenotype in DA
neurons. Factors used in the differentiation of mouse ES cells, such as
FGF8 and SHH, also induce DA neurons when added to neuroepithelial
cells derived from human ES cells [136]. Genetic modiﬁcation may
also be needed to produce enriched DA neurons from ES cells. A recent
study showed that forced introduction of Lmx1a into mouse and
human ES cells dramatically promoted midDA neurons up to 50–95%
[137].
Interestingly, to generate midDA neurons from human ES cells, co-
culture with stromal cells or midbrain astrocytes appears to enhance
midbrain characteristics [138–143]. The responsible molecules and
the mechanisms of facilitated differentiation by stromal cells are still
unknown and require additional study. The combination of genetic
manipulation by Nurr1 with the signals from the feeder layer of
stromal cells and growth factors, including SHH, FGF8 and ascorbate,
enhanced the expression levels of TH, DAT, AADC and G-protein-
regulated inwardly rectifying K+ channel 2 and induced a large
proportion (approximately 90%) of DA neurons [144]. However, for
future clinical applications, efﬁcient production of midDA neurogen-
esis is needed and the avoidance of unwanted cell contamination is
required. Another problem that must be solved is the formation of
teratomas that may occur after transplantation of ES cell-derivedmidDA neurons because of the contamination of undifferentiated ES
cells.
4.3. Induced pluripotent stem (IPS) cells
Although further characterization is needed, IPS cells appear to
have similar capabilities as ES cells. They showed unlimited self-
renewal capacity and can be differentiated into different cell types of
the body. Initially, the ES cell-speciﬁc genes, Oct3/4, Sox2, c-Myc and
Klf4, were ectopically expressed to reprogram differentiated mouse
ﬁbroblasts to pluripotent cells and designated these as IPS cells [3].
The factors appear to reprogram the somatic cells to become ES-like
cells. However, the molecular mechanisms underlying how ectopi-
cally introduced ES-speciﬁc genes are turned off during differentiation
are not clearly understood. IPS cells also resulted in the formation of
teratomas containing all three germ layers when transplanted into
nude mice and contributed to embryonic development when injected
into blastocysts [3]. Using the same four reprogramming factors,
human IPS cells were successfully generated from human somatic
cells [4,5]. Although Nanog appears to be unnecessary for IPS cell
generation, the combination of Oct4, Sox2, Nanog and Lin28 were
sufﬁcient to reprogram human somatic cells to express telomerase
activity and cell surface markers and genes that are speciﬁc to human
ES cells [6]. Due to the low frequency and long time periods required
to generate IPS cells, it was suggested that IPS cells are generated by a
stochastic process [145]. In addition, it has been postulated that the
reprogramming factors are unlikely to interact with the lineage-
speciﬁc transcription factors and may require several rounds of cell
division to convert somatic cells to pluripotent cells [145]. No matter
what the mechanisms are, it seems plausible that reprogramming
factors cause a change in the chromatin to its primitive state, resulting
in a pluripotent response to extrinsic stimulus and show ES cell-like
characteristics [146]. It has been reported that ES cells have bivalent
marks of H3K4me3 and H3K27me3 on high-CpG promoters, whereas
differentiated cells are monovalent. Only few populations (about
1.2%) of somatic cells respond to deﬁned reprogramming factors and
the expressed genes of successfully generated IPS cells were highly
similar, but not identical, to that of ES cells [146]. Genes involved in
the maintenance of pluripotency and self-renewal, including Oct4,
Sox2, Nanog, Lin28, Zic3, Fgf4, Tdgf1 and Rex1, were highly expressed,
whereas genes related to lineage-speciﬁc transcription factors were
expressed at low levels [146].
Since, the use of IPS cells can overcome the ethical problems
associated with the use of ES cells and reduce the possibility of
immune rejection, if solutions are available for technical limitations
such as genetic modiﬁcation by viral infection, long-term safety, and
the production of the right types of cells, IPS cells may be used as
attractive source for cell therapy. IPS cells could be generated from
somatic cells, not only from ﬁbroblasts, but also from lymphocytes,
hepatocytes and gastric cells [3,146–150]. Fascinatingly, disease-
speciﬁc IPS cells, including spinal muscular atrophy (SMA), Hunting-
ton's disease, lateral sclerosis and muscular dystrophy, have also been
successfully generated [151,152]. Disease speciﬁc IPS cells also show
ES cell-like phenotypes in their proliferation and differentiation.
Furthermore, Ebert and colleagues [153] have reported interesting
results by showing SMA-related changes in IPS cells derived from a
type I SMA patient. Although the generation of motor neurons and
astrocytes were not initially affected in the disease-based IPS cell
model, the IPS cells derived from the SMA patient selectively hindered
motor neuron production and survival at later time points, suggesting
that IPS cells, indeed, can be used as a model to screen potential drugs
[153]. Recently, it is shown that IPS cells can successfully be derived
from skin biopsies of idiopathic parkinsonian patients [154]. Inter-
estingly, Soldner and colleagues could remove the ectopically
introduced reprogramming factors by genetic manipulation and
these cells resembled ES cells more than those retained the factors
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efﬁciencies similar to non-PD patient-derived IPS cells or hES cells
[154]. Thus, IPS cells have recently been recognized as an interesting
and valuable type of cell that may be used to study the pathological
mechanisms of neurodegeneration.
IPS cells generated from mouse ﬁbroblasts were able to differen-
tiate into neural progenitors and further into neurons and glia [155].
Upon transplantation into fetal mouse brains, these cells migrated and
differentiated into various subtypes of neurons including glutaminer-
gic, GABAergic and catechoaminergic neurons and glia. IPS cells could
be induced to differentiate into DA neurons and provide behavioral
improvement in 6-OHDA-legioned rats. These results suggest that IPS
cells behave similarly to ES cells and have potential for cell therapy for
neurodegenerative diseases.
Genomic stability is important for therapeutic application because
alterations of genome can result in detrimental diseases such as
cancer. It is reported that most IPS cells derived from both rodent and
human appear to have normal karyotype. However, like ES cells that
have been reported to gain of chromosomes 17q and 12 when
passaged as single cells, some continuously passaged IPS cells as single
cells on Matrigel resulted in appearance of chromosomal abnormal-
ities [156–158]. It is interesting to note that small portion of long-term
hNSC cultures also bears chromosomal abnormality and culture
environmental cues were related with the selection of speciﬁc hNSC
aneupoidies such as trisomy of chromosome 7 [159]. Thus, use of stem
cells for regenerative medicine requires additional culture condition
optimization and cautions to avoid genome abnormalities.
Despite the pluripotency of IPS cells, several differences suggest
that IPS cells are not identical to ES cells. It seems clear that further
research is needed to characterize IPS cells and to reﬁne/adjust
protocols for clinical use.
4.4. Mesenchymal stem cells (MSC)
Mesenchymal stem cells (MSC) are derived from bonemarrow and
can differentiate into adipocytic, osteocytic and chondrocytic lineages
[160]. Since these cells may give rise to neurons and myocardium,
MSC were considered an interesting source of cells for clinical use
[161,162]. One of the advantages of using these cells in PD is that, if
they can give rise to DA neurons, there is little possibility that immune
rejection will take place because these cells can be easily derived from
patients. In addition, the use of an autograft overcomes the ethical
problems related with ES cells. However, recent in vivo data suggested
that these “transdifferentiation” phenomena were actually mediated
by cell fusion [163–167]. Despite concerns related to cell fusion in
some cases, MSC differentiate into neurons when Notch intracellular
domain is introduced and treated with FGF2, forskolin and ciliary
neurotrophic factor [168]. Furthermore, TH-positive neuron numbers
increased when GDNF was added and functional recovery of motor
control was also observed in 6-OHDA-lesions rats [168]. Thus,
additional cautious studies are necessary to determine the potential
of using MSC for cell therapy.
5. Transplantation of stem cells or stem cell-derived DA neurons
into PD model
PD has been intensively studied by use of animal models and the
availability of these experimental models has contributed to our
understanding of the effects of cell therapy [169,170]. There are many
factors that contribute to cell survival after transplantation, such as
the age of host and the degree of neurodegeneration [169,170]. Cells
survived better when injected into young animals and into the
damaged brain, compared to intact control. When transplanted into a
parkinsonian disease animal model, 6-hydroxydopamine (OHDA)-
lesioned rats, mouse ES cells spontaneously produced TH-positive
neurons and improved motor behavior [171]. However, for therapeu-tic purposes, differentiated neural progenies, instead of ES cells,
should be used as donors to avoid the formation of teratomas.
Recently, it has been reported that multipassaged neural precursor
cells from hES cells easily underwent cell death after transplantation
[172]. Forced expression of Bcl-XL and SHH is suggested to overcome
cell death problem without increasing tumor formation [172].
A few studies attempted to generate DA neurons by overexpres-
sing Nurr1 in stem cells [33,68,80,173]. Ectopic expression of Nurr1 in
NSC line C17.2 induced neurogenesis without a DA phenotype and
when these cells were co-cultured with type 1 astrocytes, neurons
bearing DA phenotypes were generated [173]. However, upon
transplantation, many cells were lost and only a few surviving cells
expressed TH [173]. When introduced into rat NSC, Nurr1 induced a
DA phenotype in vitro, but upon transplantation in a parkinsonian
model, only a few cells survived and no motor function improvement
was observed [124]. These data suggest that NSC may require
additional factors to generate DA neurons in addition to Nurr1.
However, in ES cells, by overexpression of Nurr1, enriched generation
of DA neurons was achieved and motor function and electrophysio-
logical improvement was obtained [174]. Introduction of FoxA2 in
addition to Nurr1 into NSC or ES cells increased generation of midDA
neurons and signiﬁcantly improvedmotor deﬁcits in an animal model
[80].
Similar to rodent cells, NSC derived from human ES cells also
survive and become functional after transplantation [175]. However,
differentiated DA neurons derived from primate ES cells survive
poorly when transplanted into 6-OHDA-lesioned rats [133,176].
Interestingly, when DA neurons differentiated from ES cells by co-
culturing with stromal cells were transplanted into the MPTP-treated
animals, they survived better and provided functional recovery of
motor control [177]. This ﬁnding indicates that, in the presence of
stromal cells, DA neurons may differentiate into a midbrain
phenotype and may be better incorporated in the striatum where
the transplantation takes place. As stated earlier, DA neurons can be
classiﬁed into three categories depending on their location, including
nigrostriatal, mesolimbic and mesocortical DA neurons, and each
group of cells possesses distinct transcriptomes and responds
differently to the toxins that induce PD [178]. Thus, it is important
to generate the correct type of midDA neurons for improved survival
and functional recovery.
6. Conclusions
As the average human life span increases, it is probable that rates
of neurodegenerative disease will also increase. Causes of PD include
exposure to neurotoxins, local damage to the head/brain, and
mutations in genes that are critical to the survival of DA neurons or
autophagy. While pharmacological treatment and brain stimulation
have been shown to reduce symptoms of PD, they are not cures. Great
technical and scientiﬁc advances have been made in the last few
decades in growing stem cells and identifying important molecular
factors that are involved in midDA neurogenesis. Although there are
still many challenges to overcome in terms of generating the right
types of DA neurons, and reﬁning conditions to increase the survival
of transplanted cells, it is promising that stem cells can be induced to
produce midDA phenotypes and have potential for cell therapy.
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